Recently, Beijing JILUNTAI Pharmaceutical Co., Ltd. ("JILUNTAI"), a nuclear medicine innovation company invested and incubated by Baheal Pharma Group, achieved a significant R&D milestone. Its independently developed Class 1 innovative therapeutic radiopharmaceutical, ¹⁷⁷Lu-JLT003 injection (generic name: ¹⁷⁷Lu-AB-3PRGD2), has officially received an Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The drug is intended for the treatment of integrin αvβ3-positive malignant tumors.

On March 9, 2026, SicaGene announced that its proprietary Class I innovative drug candidate, SG12 Injection (“SG12”) for the treatment of chronic hepatitis B (CHB), has received Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA).

On December 25th, 2025, RabPharma Biopharma Co., Ltd. (“RabPharma”) announced that the Investigational New Drug (IND) application for a new indication of its core pipeline candidate, RAB001 for injection, has been approved by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA). The newly approved indication expands the clinical development of RAB001 into knee osteoarthritis, marking the second IND approval obtained for this innovative bone regenerative therapy. The IND approval (Acceptance No. CXHL2501164) represents an important milestone in broadening the clinical application of RAB001 from osteonecrosis to osteoarthritis, one of the world’s most prevalent degenerative musculoskeletal diseases.

Baheal Pharma Group has been named among the "Top 30 Strategic Investors / CVCs in China" in Zero2IPO Research Center's 2025 China Venture Capital & Private Equity Annual Ranking, reflecting the Group’s sustained commitment and proven track record in healthcare innovation investment and incubation.

Baheal Medical (301015.SZ) is accelerating the implementation of its integrated radiotherapy strategy centered on precision oncology technologies, building a full-cycle ecosystem encompassing global technology introduction, China-based manufacturing for worldwide supply, precision radiotherapy center development, and evidence-based clinical research. Between 5th-9th December 2025, Baheal announced a series of major milestones surrounding the ZAP-X® Gyroscopic Radiosurgery System, including the launch of a global manufacturing and supply center, the initiation of large-scale clinical studies, and the continued expansion of precision radiotherapy centers in China. Together, these developments mark a new stage of large-scale, standardized clinical adoption of ZAP-X in China and reflect the accelerating execution of Baheal's long-term radiotherapy strategy.